PA-RELIEF-THERAPEUTICS
29.7.2020 07:32:11 CEST | Business Wire | Press release
RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTC:RLFTF) “Relief” and its U.S. partner, NeuroRx, Inc. today announced that FDA has granted an Expanded Access Protocol for treatment of Respiratory Failure in COVID-19 with RLF-100 (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP). The protocol makes treatment available to patients who have exhausted standard therapies and are not eligible for the current phase 2/3 trial of RLF-100 because of confounding medical conditions and specifically makes the treatment available to pregnant women. Although the drug remains under investigation, rapid recovery from respiratory failure in COVID-19 has been seen in patients treated under FDA Emergency Use authorization.1
The expanded access protocol may be viewed on www.clinicaltrials.gov NCT04453839. Physicians who wish to enroll their patients in the protocol must submit the protocol to their local investigational review board and file FDA form 1572 with NeuroRx, Inc. Further information may be obtained from expandedaccess@neurorxpharma.com .
“By granting this Expanded Access protocol, FDA has made a potentially lifesaving drug immediately available to critically ill patients who have no other available treatment,” said Dr. Jonathan C. Javitt, MD, MPH, NeuroRx’s CEO. “We thank the FDA’s pulmonary division for its rapid and proactive implementation of the Coronavirus Treatment Acceleration Program, and we aspire to demonstrate broad safety and efficacy for RLF-100 in our ongoing clinical trial .”
The SARS-CoV-2 coronavirus that causes COVID-19 attacks the body by entering the small population of Alveolar Type II cells in the lung.2 Without Type II cells, the lung cannot transmit oxygen, which why the coronavirus causes acute respiratory failure. 50 years of scientific research demonstrates that VIP binds specifically to the Type II cell and protects that cell against cytokines (inflammatory molecules) and a wide array of toxic and infectious injuries.”3
About RELIEF THERAPEUTICS Holding AG
The Relief group of companies focus primarily on clinical-stage projects based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rational. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications.
Relief Therapeutics holds orphan drug designations from the U.S. Food and Drug Administration and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief Therapeutics also holds a U.S. patent4 for RLF-100 and proprietary manufacturing processes for its synthesis.
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF (ISIN: CH0100191136).
About NeuroRx, Inc.
NeuroRx draws upon more than 100 years of collective drug development experience and is led by former senior executives of Johnson & Johnson, Eli Lilly, Pfizer, and AstraZeneca, PPD. In addition to its work on RLF-100, NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 for the treatment of suicidal bipolar depression and is currently in Phase 3 trials.
Disclaimer : This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, NeuroRx, Inc. and their businesses. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG and/or NeuroRx, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
1 Youssef JG, Rapid Clinical Recovery from Critical COVID-19 with Respiratory Failure in a Lung Transplant Patient Treated with Intravenous Vasoactive Intestinal Peptide doi: 10.20944/preprints202007.0178.v1
2 Mason R. Pathogenesis of COVID-19 from a Cell Biologic Perspective. Eur Respir J. April 9 Epub ahead of print. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144II60/
4 US 8,178,489 Formulation for Aviptadil
View source version on businesswire.com: https://www.businesswire.com/news/home/20200728005828/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Belkin Expands Nintendo Switch 2 Accessories Ecosystem With New Charging Grip and Travel Bag4.6.2026 18:00:00 CEST | Press release
Following the January debut of Charging Case Pro, Belkin broadens its gaming portfolio with new ways to power, carry, and play Today, Belkin, a leading consumer electronics brand for 40 years, announced the expansion of its Nintendo Switch 2 accessories ecosystem with the launch of the GamingCharging Grip for Nintendo Switch 2 and Gaming Travel Bag for Nintendo Switch 2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604082278/en/ Belkin expands Nintendo Switch 2 accessories ecosystem with new Charging Grip and Travel Bag Following the January debut of the award-winning Charging Case Pro, the new accessories build on Belkin’s growing gaming portfolio, offering players more ways to power, protect and carry their gaming essentials wherever they play. After entering the gaming accessories category in June 2025, Belkin continues to expand its ecosystem with thoughtfully designed products that combine premium materials, practi
DEWA Opens Registration for WETEX 20264.6.2026 17:55:00 CEST | Press release
Dubai Electricity and Water Authority (DEWA) has opened registration for the 28th edition of the Water, Energy, Technology and Environment Exhibition (WETEX), which will take place from 20 to 22 October 2026 at the Dubai World Trade Centre. One of the leading specialised exhibitions of its kind in the world and the largest in the region, WETEX is convened by DEWA under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604642265/en/ DEWA opens registration for WETEX 2026 (Photo: AETOSWire) WETEX covers a wide range of sectors, including energy, water, environment, green development, digital transformation, artificial intelligence (AI), sustainability, decarbonisation, green mobility, green hydroge
LotusFlare’s DNO™ Cloud Powers the Launch of Pi in South Africa4.6.2026 17:49:00 CEST | Press release
LotusFlare, a leading provider of cloud-native, AI-driven digital commerce and monetization platforms for communications service providers (CSPs), today announced its partnership with MTN South Africa to power the launch of its new digital brand, Pi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604149542/en/ At the core of Pi is LotusFlare’s DNO™ Cloud—a fully digital, cloud-native BSS platform that enables delivering a seamless, app-first customer experience at scale. From onboarding to plan management, Pi customers can access 5G mobile, fixed wireless, and travel eSIM services within minutes—without contracts, credit checks, or call centres—through a single, intuitive interface. DNO™ Cloud underpins the entire Pi ecosystem, including front-end digital experiences, product catalog, order management, converged charging, billing, and eSIM orchestration. Deployed on public cloud infrastructure in compliance with South Afr
INRIX Sets the Standard for Predictive and Accurate Parking Intelligence4.6.2026 17:42:00 CEST | Press release
INRIX now has the most parking data in the industry covering 22K cities and 48M spaces INRIX, Inc., a global leader in transportation intelligence, today announced a significantly expanded deployment of its predictive parking and curb intelligence platform, reinforcing its position as the industry’s most comprehensive and decision-grade parking intelligence solution for automotive OEMs, cities, and mobility platforms worldwide. INRIX provides real world coverage based on how parking actually works on-street, off-street, dynamic availability and driver behavior. Others count locations. INRIX understands parking ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604808273/en/ Parking Intelligence for a New Era of Mobility Parking Intelligence for a New Era of Mobility Parking data has traditionally been evaluated based on volume, how many locations are listed, or how many attributes are captured. But as mobility evo
Steady concentration PD with the Carry Life UF system increased ultrafiltration nearly threefold and sodium removal nearly tenfold vs 2.5% dextrose CAPD, while improving glucose efficiency and supporting enhanced fluid management in PD patients4.6.2026 16:45:00 CEST | Press release
Triomed AB today announced positive results from a prospective, multicenter, randomized, crossover study evaluating steady concentration peritoneal dialysis using the Carry Life UF system in adult patients undergoing CAPD. The study demonstrated significant improvements in ultrafiltration, peritoneal sodium removal and glucose ultrafiltration efficiency (ultrafiltration volume in relation to glucose absorption) compared with standard 2.5% dextrose CAPD in the home setting over four weeks. The study results were presented as a Focussed Oral presentation based on a late-breaking clinical trial abstract at the European Renal Association (ERA) Congress in Glasgow, United Kingdom, and simultaneously published in the Journal of the American Society of Nephrology (JASN). In this study, participants received their standard CAPD treatment during the control arm, whereas in the Carry Life UF arm, one daily 2.5% dextrose exchange was replaced by a Carry Life UF treatment three days per week, and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom